Senescent cells are cells that have permanently stopped dividing, often in response to DNA damage or stress. Rather than simply retiring quietly, they remain metabolically active and secrete a cocktail of proinflammatory molecules known as the senescence-associated secretory phenotype, or SASP. While this process plays a role in wound healing and tumor suppression in the short term, the gradual accumulation of senescent cells in tissues drives chronic inflammation and has been implicated in conditions ranging from frailty and diabetes to liver fibrosis and cancer. Eliminating these cells, an approach called senolysis, has therefore become one of the most actively pursued strategies in geroscience.

The problem, according to the research team led by Jianghao Qian and Akiko Takahashi, is that most current senolytic drugs work by targeting antiapoptotic pathways that senescent cells deploy to avoid self-destruction. These drugs, including the best-known combination of dasatinib and quercetin, can be effective but carry dose-dependent toxicity that limits their clinical utility. The Japanese team set out to find a fundamentally different way to kill senescent cells, and their search led them to an unexpected candidate: a forty-year-old immunosuppressant sitting in hospital pharmacies around the world.

Their findings reveal that cyclosporine A kills senescent cells through paraptosis-like cell death, a caspase-independent process that does not rely on the conventional apoptosis machinery targeted by existing senolytics. In paraptosis, cells die through dramatic swelling and vacuolization of the endoplasmic reticulum and mitochondria rather than through the orderly fragmentation characteristic of apoptosis. Using live-cell holotomography imaging, the researchers directly visualized this distinctive death process unfolding in senescent cells treated with the drug.

The mechanism behind this selectivity is elegant in its exploitation of a senescent cell’s own weakness. The team discovered that cyclosporine A activates JNK signaling and elevates production of reactive oxygen species, which in turn triggers the apoptosis signal-regulating kinase 1, or ASK1, and its downstream partner, the p38 mitogen-activated protein kinase pathway. Rather than suppressing inflammation as it does in immune cells, the drug amplifies SASP factor expression in senescent cells, dramatically increasing their secretory output.

This SASP overactivation turns out to be lethal precisely because senescent cells are already operating at the limit of their protein-handling capacity. The researchers showed that senescent cells inherently exhibit chronic adaptive endoplasmic reticulum stress responses and heightened ER functional demands, a direct consequence of their extensive secretory activity. The endoplasmic reticulum is the cellular organelle responsible for folding and processing the vast majority of secreted proteins, and the constant flood of inflammatory SASP factors places an enormous burden on this system. When cyclosporine A further disrupts this fragile ER homeostasis by forcing SASP overexpression, the organelle swells catastrophically, and the cell succumbs to paraptosis-like death.

In other words, the very trait that makes senescent cells harmful to tissue, their relentless secretion of inflammatory mediators, becomes the vulnerability that cyclosporine A exploits. Healthy nonsenescent cells, which do not carry this chronic ER stress burden, tolerate the drug at concentrations that prove lethal to their senescent counterparts, providing a mechanistic basis for the drug’s selectivity.

The therapeutic implications were tested directly in an animal model of obesity-associated liver cancer. Obese mice accumulate senescent hepatic stellate cells in their livers, and these cells promote the development of hepatocellular carcinoma by sustaining the inflammatory microenvironment that feeds tumor growth. When the researchers treated obese mice with cyclosporine A, the drug eliminated the senescent stellate cells from the liver and, remarkably, prevented the development of obesity-associated hepatocellular carcinoma. This finding suggests that senolysis via paraptosis could be deployed not merely to slow aging but to intervene in specific cancers driven by senescent cells in the tumor microenvironment.

The study represents a significant conceptual expansion of the senolytic toolkit. By demonstrating that ER stress-induced paraptosis-like cell death can serve as a viable senolysis strategy, the work establishes an entirely new mechanistic class of senotherapy, one that targets the proteostatic fragility of senescent cells rather than their apoptotic defenses. Because cyclosporine A is already an approved clinical drug with well-characterized pharmacology, the path from bench to bedside could be considerably shorter than for entirely novel compounds, although the researchers caution that dose, duration, and the drug’s immunosuppressive effects will all need careful evaluation in the context of senotherapy.

More broadly, the findings add to a growing recognition that aging cells can be eliminated by exploiting metabolic and stress-response vulnerabilities unique to their state. If ER stress amplification proves safe and effective in humans, the strategy could eventually be applied across a broad spectrum of age-related disorders, from fibrotic liver disease to inflammation-driven tumors, offering a way to turn a decades-old transplant drug into a weapon against the biology of aging itself.

Subject of Research: Senolysis via cyclosporine A-induced endoplasmic reticulum stress and paraptosis-like cell death in senescent cells

Article Title: Cyclosporine A provokes paraptosis-like cell death in senescent cells by triggering endoplasmic reticulum stress

Article References: Qian, J., Zhou, X., Lee, K.-S., Loo, T. M., Tanaka, Y., Sugawara, S., Hanyu, A., Kawasaki, H., Yotsumoto, S., Dodo, K., Shirasaki, Y., Kamatani, T., Tanaka, K., & Takahashi, A. (2026). Cyclosporine A provokes paraptosis-like cell death in senescent cells by triggering endoplasmic reticulum stress. Genome Biology. https://doi.org/10.1186/s13059-026-04273-x

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04273-x

Keywords: cellular senescence, senolysis, cyclosporine A, endoplasmic reticulum stress, paraptosis, SASP, hepatocellular carcinoma, aging, cell death, senolytics, Cyclosporine, provokes

CD44 is far from an obscure protein. First identified decades ago as the principal cell surface receptor for hyaluronan, the large sugar molecule that gives many tissues their hydrated structure, CD44 rose to fame in cancer biology as a marker of tumor-initiating stem cells. Yet as the new review makes clear, the same structural features that make CD44 useful to tumors also make it a pivotal player in normal aging. The receptor is not a passive anchor. Through its extracellular domains, it binds hyaluronan, osteopontin, and other matrix components; through its cytoplasmic tail, it connects to the actin cytoskeleton,Src-family kinases, and an array of signaling complexes. Its gene can be spliced into dozens of different isoforms, each with distinct properties, and it can be cleaved by proteases to release fragments, including the intracellular domain known as CD44-ICD, that travel to the nucleus and alter gene expression. In effect, CD44 is a molecular switchboard with the ability to rewire a cell’s response to its surroundings.

The review’s central argument concerns how a remodeling extracellular matrix uses CD44 to drive what researchers call inflammaging, the low-grade chronic inflammation that accompanies aging. In young, healthy tissue, the matrix is rich in high-molecular-weight hyaluronan, a long-chain polymer that generally supports tissue integrity and even exerts protective effects. As tissues age, hyaluronan breaks down into shorter fragments, and the balance of matrix components shifts. These smaller fragments can engage CD44 together with innate immune receptors such as the toll-like receptors, activating the transcription factor NF-κB. NF-κB, in turn, switches on the production of pro-inflammatory cytokines and chemokines. The review emphasizes that this process is not uniform across the body. In vascular tissue, the release of fragmented hyaluronan drives a different arm of the response, the CD44-STAT3 axis, which suppresses autophagic flux and pushes endothelial cells into a senescent state. Senescent cells themselves secrete inflammatory signals, creating a feedback loop that sustains chronic inflammation long after the initial trigger has passed.

The mechanistic connection between CD44 and autophagy, the cellular recycling system, has emerged from recent work that the review highlights as foundational. A 2023 study in Nature Communications demonstrated that CD44 activation by hyaluronan fragments in vascular endothelium activates STAT3, which in turn suppresses the class III PI3K complex that is essential for initiating autophagy. The result is a decline in the cell’s ability to clear damaged proteins and organelles, a decline long recognized as one of the hallmarks of cellular aging. By placing CD44 upstream of this process, the review provides a coherent mechanistic explanation for why an aging matrix might directly cause a decline in cellular housekeeping, and it suggests that blocking CD44 signaling in the vasculature could preserve autophagy and delay endothelial senescence.

What makes the story more complex, and more intriguing, is that CD44’s effects are deeply context-dependent. The receptor is not a single entity but a family of isoforms generated by alternative splicing, and different tissues, and even different cells within the same tissue, express different combinations. In some settings, CD44 signaling promotes tissue repair and proteostasis. The naked mole-rat, a rodent famous for its exceptional longevity, produces very-high-molecular-mass hyaluronan that engages CD44 in ways that appear to enhance resistance to stress, and recent work has linked CD44 to enhanced activity of the ATF6 branch of the unfolded protein response, a key defense against endoplasmic reticulum stress. In other settings, such as kidney tubules under acute injury or liver fibrosis, CD44 signaling through NF-κB drives mitochondrial dysfunction and tissue scarring. The review argues that isoform switching and proteolytic processing determine which of these programs a cell enters, meaning that the same receptor can be a driver of degeneration or a support for regeneration depending on which version of the protein is on the surface and which fragments have been released into the cell.

New technologies are now revealing how precisely this dysregulation is patterned across the body. Single-cell RNA sequencing and spatial transcriptomics, which allow researchers to measure gene expression in individual cells while preserving information about their location, have shown that CD44 and its variant isoforms are not uniformly altered with age. Instead, specific cell populations within the vasculature, brain, adipose tissue, kidney, and liver show distinct patterns of CD44 upregulation or isoform switching. In the brain, astrocytes in aged tissue produce excess hyaluronan, potentially creating a matrix environment that limits neural stem cell function. In adipose tissue, genome-wide association studies have linked CD44 expression to type 2 diabetes, and anti-CD44 antibody treatment in obese mice has been shown to lower hyperglycemia and reduce inflammation in fat and liver. In kidney, CD44 expression in tubular cells has been tied to NF-κB p65-mediated mitochondrial dysfunction during acute injury. These findings suggest that targeting CD44 would need to be tissue-specific and stage-specific rather than a single global intervention.

The review also explores the possibility that CD44 acts as a mechanosensor, translating physical forces in the extracellular matrix into biochemical signals. Molecular dynamics simulations have revealed how the binding of hyaluronan to CD44 can be regulated by mechanical force, suggesting that the receptor may be one of the ways in which cells sense the stiffness and architecture of their surroundings. Because tissue stiffness changes with age, this places CD44 at the interface between the mechanical and biochemical dimensions of aging biology. It also connects the field to a broader realization, increasingly prominent in the literature, that the mechanical properties of the aging matrix are not merely a consequence of aging but an active driver of cellular behavior.

From a therapeutic standpoint, the review is cautiously optimistic. Because CD44 sits at the junction of matrix remodeling and intracellular signaling, it offers multiple points of intervention. Ligand competition, using soluble hyaluronan-binding molecules to prevent fragmented hyaluronan from engaging the receptor, could reduce inflammatory signaling. Antibody blockade, already tested in metabolic disease models, could modulate CD44 activity in specific tissues. γ-secretase modulation, which influences the release of the CD44-ICD nuclear fragment, could alter the receptor’s transcriptional effects. In tendinopathy, lentiviral gene therapy targeting CD44 has already been shown to reduce senescence-associated secretory phenotypes in experimental models. The review notes that the clinical translation of these strategies will require a much deeper understanding of when CD44 signaling is harmful and when it is protective, but the framework it presents suggests that such a distinction is now mechanistically tractable.

Perhaps the most significant contribution of the review is conceptual. By establishing CD44 as the mechanistic link between extracellular matrix remodeling and nuclear responses in aging, it provides a bridge between two fields that have largely developed in parallel. Those studying the hallmarks of aging have focused on intracellular processes such as genomic instability, mitochondrial dysfunction, and loss of proteostasis. Those studying the extracellular matrix have focused on fibrosis, stiffness, and matrix degradation. CD44 sits at the boundary, translating one into the other. If the framework holds up under further experimental scrutiny, it suggests that interventions aimed at preserving matrix quality, or at modulating how cells read the matrix, could have effects on aging that extend far beyond the tissue in which they are applied. In a field where the search for effective interventions to extend health span has often focused on cells themselves, the message of this review is that the ground in which those cells are embedded may be just as important a target.

Cellular senescence is a protective state that prevents damaged or stressed cells from continuing to proliferate. Senescent cells withdraw from the cell cycle, but they do not become biologically inactive. Many release a complex mixture of signaling molecules known as the senescence-associated secretory phenotype, or SASP. This secretome can include inflammatory cytokines, chemokines, growth factors and interferon-stimulated genes, commonly called ISGs. In the short term, these signals can help coordinate tissue repair or alert the immune system. When senescent cells accumulate with age, however, persistent SASP activity may contribute to tissue dysfunction, chronic inflammation and age-related disease.

The new work focuses on a molecular contradiction at the center of senescence biology. CCND1 is best known for helping cells progress through the early stages of the cell cycle. It binds to cyclin-dependent kinases, particularly CDK4 and CDK6, to promote phosphorylation of retinoblastoma-associated cell-cycle regulators and enable progression toward DNA replication. Senescent cells are not supposed to advance through this process, yet the researchers found that CCND1 is consistently increased across multiple models of nonproliferating senescent cells. The study extends earlier observations by showing that this elevation is not merely a marker of senescence. Instead, CCND1 and CDK6 actively contribute to the inflammatory state.

According to the findings, the CCND1–CDK6 complex promotes the accumulation of DNA damage in senescent cells. DNA damage can arise from replication stress, oxidative injury, defective repair or abnormal activity at fragile regions of the genome. In cells that have exited the cell cycle, damaged DNA may persist because repair processes and chromatin organization are altered. The researchers link increased CCND1–CDK6 activity to a greater burden of DNA damage, creating a chain reaction that connects cell-cycle regulators with innate immune signaling. This connection helps explain how a protein traditionally associated with proliferation can influence the behavior of cells that are no longer dividing.

One consequence of this damage is the production of cytoplasmic chromatin fragments. These are pieces of nuclear DNA or chromatin that become displaced into the cytoplasm, where they can be interpreted as danger signals. The immune sensor cyclic GMP–AMP synthase, or cGAS, recognizes abnormal double-stranded DNA in the cytoplasm and generates the second messenger cyclic GMP–AMP. That molecule activates the adaptor protein STING, which in turn stimulates downstream kinases and transcription factors, including pathways controlled by TBK1 and interferon regulatory factors. The result is the expression of interferon-stimulated genes and other inflammatory programs. By placing CCND1–CDK6 upstream of DNA damage, cytoplasmic chromatin fragments and cGAS–STING signaling, the study outlines a mechanistic route from senescence to inflammation.

The investigators examined this relationship in cellular systems designed to model senescence and found that reducing CCND1 or inhibiting CDK6 weakened the inflammatory output. The findings indicate that the pathway is not simply associated with the presence of senescent cells but helps determine how strongly those cells activate SASP and ISG programs. This distinction is important because senescence is not a single uniform state. Different triggers, including oncogene activation, DNA damage, oxidative stress and replicative exhaustion, can produce cells with overlapping but distinct secretory profiles. A pathway that regulates inflammatory signaling across several models could therefore offer a broader intervention point than therapies aimed at eliminating only one type of senescent cell.

The study also examined aging in living animals, focusing on the liver. Hepatocytes, the liver’s principal functional cells, can acquire senescence-like features as organisms grow older. In aged mouse livers, the researchers observed increased expression of Ccnd1 in senescent hepatocytes, together with signatures of DNA damage and interferon-related activity. To test whether CCND1 was functionally involved, they used a hepatocyte-specific Ccnd1 knockout model. Removing the gene from these liver cells reduced DNA damage and lowered expression of ISGs in aged animals. The results support the idea that elevated CCND1 is not only a consequence of aging-associated cellular stress but also a driver of inflammatory signaling within the aging liver.

The researchers then tested palbociclib, a clinical-grade inhibitor of CDK4 and CDK6. Palbociclib is already used in oncology, particularly for hormone receptor-positive breast cancer, where it restrains tumor-cell proliferation by interrupting cyclin-dependent kinase signaling. In the aged mice, treatment with the drug reduced DNA damage and interferon-stimulated gene expression in the liver, mirroring key effects seen after hepatocyte-specific Ccnd1 deletion. The study further reports that palbociclib-treated aged mice showed less frailty and improved physical performance. These outcomes suggest that dampening CCND1–CDK6 signaling may influence not only molecular markers of inflammation but also whole-animal measures of functional decline.

The findings are particularly notable because they point toward therapeutic repurposing rather than the immediate development of an entirely new drug class. Senolytic drugs are designed to selectively eliminate senescent cells, while senomorphic or senostatic approaches attempt to suppress harmful features such as SASP without necessarily removing the cells. Inhibiting CDK4/6 may fit within the second category by reducing the DNA-damage and inflammatory circuitry of senescent cells. However, the pathway also has essential roles in normal tissues, and CDK4/6 inhibitors can produce clinically important effects, including changes in blood-cell production and other treatment-related toxicities. The study used aged mice, not human patients, so its results do not establish that palbociclib will prevent frailty or extend healthy lifespan in people.

The work nevertheless provides a new framework for understanding why senescent cells can remain inflammatory long after they stop dividing. CCND1 appears to have a second life in senescence: instead of simply pushing cells through the cell cycle, its partnership with CDK6 may help sustain genomic damage and activate the cGAS–STING system. By reducing this activity, genetic deletion and pharmacological inhibition lowered inflammatory gene expression in aged liver and were associated with better physical function in mice. Future studies will need to determine how broadly the mechanism operates across organs, whether treatment windows can be identified that preserve beneficial senescence responses, and whether the benefits observed in animals can be translated safely to older people. For now, the findings place the CCND1–CDK6 axis among the emerging molecular targets connecting cellular aging, DNA damage and chronic inflammation.

Subject of Research: The role of cyclin D1–CDK6 signaling in senescence-associated inflammation, DNA damage, cGAS–STING activation and age-related functional decline.

Article Title: Inhibiting cyclin D1–CDK6 suppresses senescence-associated inflammatory gene expression and age-related functional decline

Article References: Rajesh, A., Havas, A.P., Arnold, R. et al. “Inhibiting cyclin D1–CDK6 suppresses senescence-associated inflammatory gene expression and age-related functional decline.” Nature Aging (2026). https://doi.org/10.1038/s43587-026-01196-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s43587-026-01196-x

Keywords: Cellular senescence, cyclin D1, CCND1, CDK6, SASP, interferon-stimulated genes, DNA damage, cGAS–STING, palbociclib, aging, frailty, liver inflammation.

Feldstein’s participation reflects the growing interest of major pharmaceutical companies in aging-related biology as a source of therapeutic opportunities. Rather than treating aging as a single disease, geroscience investigates the interconnected biological processes that increase vulnerability to multiple age-associated conditions. These processes can include cellular senescence, chronic inflammation, mitochondrial dysfunction, loss of proteostasis, epigenetic alterations, impaired tissue repair and declining immune function. Researchers increasingly hope that interventions aimed at these mechanisms could delay or reduce the risk of several diseases simultaneously, extending the period of life spent in good health rather than merely increasing total lifespan.

That scientific shift has created a new class of drug-development questions. Researchers must determine which biological features of aging are causally responsible for disease, which can be safely modified, and how those changes can be measured in humans. Potential indicators include molecular signatures in blood, DNA-methylation patterns, inflammatory markers, imaging measurements, physical-performance data and composite assessments of biological age. Yet a biomarker is not automatically a therapeutic target, and a change in biological age does not necessarily demonstrate that a treatment will prevent disease. Establishing clinically meaningful endpoints remains one of the central challenges facing longevity medicine.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He said the field must combine a deeper understanding of aging with the development of interventions that improve healthspan, the period of life spent in relatively good health. According to Gladyshev, progress will require collaboration across disciplines and sectors, because discoveries in molecular biology must ultimately be tested through rigorous translational and clinical research.

ARDD 2026 is being presented as a meeting point between those stages of discovery. Academic laboratories are investigating the molecular architecture of aging, while biotechnology companies are developing programs designed to influence senescent cells, immune aging, metabolic regulation, tissue regeneration and other age-related pathways. Pharmaceutical companies bring experience in medicinal chemistry, toxicology, clinical-trial design, manufacturing and regulatory strategy. Investors, meanwhile, are evaluating whether emerging longevity technologies can produce reproducible clinical benefits at a scale compatible with modern health-care systems.

The conference will include leaders from ten of the world’s major pharmaceutical companies and a broad network of sponsors from the pharmaceutical, biotechnology, nutrition, diagnostics, finance and consumer-health sectors. Insilico Medicine and Eli Lilly are identified as Tier 1 sponsors, with the McKinsey Health Institute serving as the sole knowledge partner. Additional sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health and TruDiagnostic. Synaro Capital, The Cat Health Company and PranaGen Bioscience are supporting the meeting as Tier 4 sponsors, while Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity and QuadraScope are listed as Tier 5 sponsors.

The commercial scale of that ecosystem illustrates how quickly longevity research has entered the mainstream of biomedical innovation. However, the expansion of investment also increases pressure on researchers and companies to distinguish scientifically validated approaches from premature claims. Aging is a complex, multiscale process, and interventions that appear beneficial in cells or laboratory animals may fail in humans because of differences in metabolism, immune response, disease history or treatment duration. For this reason, the most consequential discussions at meetings such as ARDD are likely to center on reproducibility, patient selection, safety, trial endpoints and the evidence required to show that a therapy changes clinically important outcomes.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the meeting’s move to Boston marks a new stage for the conference. Boston and the surrounding region form one of the world’s most concentrated biomedical research and drug-development ecosystems, linking universities, hospitals, biotechnology companies and pharmaceutical organizations. Scheibye-Knudsen described ARDD 2026 as increasingly focused on translating discoveries into medicines, a transition that requires researchers to connect fundamental mechanisms of aging with practical therapeutic programs.

Alex Zhavoronkov, Ph.D., co-chair of ARDD and chief executive officer of Insilico Medicine, said the meeting has served for more than a decade as a platform for dialogue among academia, pharmaceutical companies, startups and investors. Insilico Medicine is officially organizing the 2026 event. The company’s role places the conference within a broader industry movement that uses artificial intelligence, large biological datasets and computational drug-discovery methods to identify targets and design candidate molecules. Such technologies may accelerate early research, but their value will ultimately depend on experimental validation and evidence from human studies.

ARDD is now in its 13th year and is described by its organizers as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 program is intended to examine how advances in the biology of aging can be converted into research-and-development strategies and therapeutic candidates. The Nordic Aging Society, a nonprofit scientific organization dedicated to aging research and collaboration across the Nordic region and beyond, is supporting the meeting. With the field approaching a decisive phase—where molecular insights must be matched by clinical evidence—the Boston gathering will offer a high-profile test of whether longevity science can fulfill its promise of producing safer, more effective interventions for age-related disease and functional decline.

Subject of Research: Aging biology, geroscience, longevity biotechnology, drug discovery and the translation of aging research into clinical therapies.

Article Title: Pfizer Executive Ariel Feldstein to Speak at ARDD 2026 as Longevity Science Enters a New Drug-Development Era

News Publication Date: Aug. 7, 2026

Web References: https://agingpharma.org; https://mediasvc.eurekalert.org/Api/v1/Multimedia/582b0698-c395-46ef-a16b-f659f75c72f4/Rendition/low-res/Content/Public

References: ARDD 2026 announcement provided by Insilico Medicine and the ARDD organizing committee; statements attributed to Vadim Gladyshev, Morten Scheibye-Knudsen and Alex Zhavoronkov.

Image Credits: ARDD 2026

Keywords: Aging research, longevity science, geroscience, drug discovery, healthspan, biological aging, biotechnology, pharmaceutical research, clinical translation, ARDD 2026, Ariel Feldstein, Pfizer

Aging is accompanied by a multitude of physiological alterations, among which sarcopenia and osteoporosis represent significant public health challenges. Sarcopenia, characterized by the gradual reduction of skeletal muscle mass and function, coupled with osteoporosis, the degradation of bone density and architecture, collectively contribute to increased morbidity, loss of independence, and higher mortality rates in older adults worldwide. The molecular mechanisms underlying these degenerative processes remain incompletely understood, complicating the development of effective interventions.

PAI-1, a serine protease inhibitor known predominantly for its regulation of fibrinolysis and blood clotting, has garnered attention due to its involvement in cellular senescence and chronic inflammation—two hallmarks of aging tissues. The study from Takashi Ohira and colleagues builds on previous insights by delineating how PAI-1 modulates musculoskeletal aging at a molecular and functional level in a mammalian model.

Employing genetically engineered mice deficient in the PAI-1 gene (PAI-1⁻/⁻), the investigators conducted a comparative analysis between young adult (6-month-old) and aged (24-month-old) cohorts of both sexes. The findings revealed that while endogenous PAI-1 expression increased significantly with chronological age across both male and female wild-type animals, the absence of PAI-1 conferred striking preservation of muscle and bone integrity exclusively in female mice.

Functionally, aged female PAI-1 knockout mice maintained substantially greater muscle mass in the gastrocnemius and soleus muscles, key components of lower limb mobility, alongside superior grip strength performance when compared with age-matched controls. Cortical bone evaluations of the femur and tibia further demonstrated attenuated osteopenic changes in these knockout females, suggesting a coordinated protective effect on both muscle and bone tissues.

Interestingly, the male PAI-1⁻/⁻ mice did not exhibit comparable resistance to age-related declines, underscoring a sex-specific interaction between PAI-1 activity and the biological pathways governing musculoskeletal aging. This sex disparity introduces new dimensions to the study of age-associated degeneration, implicating hormonal or genomic factors that may modulate PAI-1’s impact.

Delving deeper into mechanisms, the research team uncovered that PAI-1 deficiency reduced inflammatory markers, including interleukin-6 (IL-6), in the systemic circulation and muscle tissues of aged female mice. IL-6 is a well-established pro-inflammatory cytokine often elevated in chronic age-related diseases, contributing to the catabolic environment that undermines tissue homeostasis. These results implicate PAI-1 as an upstream regulator of inflammatory cascades that exacerbate sarcopenia and osteoporosis.

Notably, the protective phenotype was not accompanied by alterations in muscle protein synthesis or degradation rates, nor by reductions in fibrotic tissue accumulation within muscle, suggesting that PAI-1’s deleterious effects are primarily mediated through inflammatory signaling rather than direct modulation of structural tissue remodeling or metabolism.

This study challenges conventional paradigms by positioning PAI-1 at the nexus of age-induced inflammatory and degenerative pathways, and reveals its significant role in mediating sex-dependent disparities in musculoskeletal aging. The findings may have profound implications for the development of targeted interventions aiming to preserve muscle and bone health in aging women, a demographic disproportionately affected by osteoporosis and frailty.

Given the global demographic shift toward older populations, identifying actionable molecular targets such as PAI-1 is critical. Interventions that modulate PAI-1 activity could potentially ameliorate the debilitating consequences of sarcopenia and osteoporosis, enhancing mobility, decreasing fall risk, and improving quality of life for millions of elderly individuals.

Further research is warranted to elucidate the precise molecular interactions between PAI-1, sex hormones, and inflammatory networks, as well as to explore translational strategies for pharmacological inhibition of PAI-1. Such studies could open new frontiers in precision medicine approaches tailored to sex-specific aging processes.

In summary, the research illuminates a previously unappreciated role for PAI-1 in orchestrating age-related musculoskeletal decline with marked female specificity, offering hope that modulation of this inhibitor could serve as an effective strategy to combat frailty and osteoporosis—a major advance toward healthier aging.

—

Subject of Research: Animals

Article Title: Roles of plasminogen activator inhibitor-1 in aging-related muscle and bone loss in mice

News Publication Date: 11-Sep-2025

Web References: http://dx.doi.org/10.18632/aging.206318

Image Credits: Copyright: © 2025 Ohira et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0)

Keywords: plasminogen activator inhibitor-1, aging, sarcopenia, osteoporosis, sex